1+ day, 4+ hour ago   (323+ words) Last week’s regulatory news saw the US Food and Drug Administration (FDA) grant accelerated approval for AstraZeneca’s Etcamah combination for the treatment of breast cancer. On the research front, Novartis suffered another setback, this time with its Phase III trial…...

5+ day, 2+ hour ago   (228+ words) The Pharma Letter MannKind inks obesity deal with Rose Pharma US biopharma company MannKind Corp (Nasdaq: MNKD) and Rose Pharma today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management....

1+ week, 7+ hour ago   (263+ words) thepharmaletter.com Regulatory round-up: 7 September 2026 Medicines regulators in major international markets have issued a mix of first-in-class approvals, safety reviews, supply and shortage measures, consultations and one authorization suspension over the past week. The latest round-up includes two clearances from…...

2+ week, 4+ day ago   (216+ words) The Pharma Letter - Galen and POA Pharma launch Galsana, a new global brand for rare metabolic diseases Northern Ireland-headquartered pharma company Galen has unveiled Galsana, a new global brand uniting its metabolic disease portfolio with that of Copenhagen-based POA Pharma,…...

3+ week, 1+ hour ago   (235+ words) The Pharma Letter - Hanmi Pharm inks obesity license deal with Genentech South Korean firm Hanmi Pharm (KRX: 128940) today announced that it has entered into an exclusive licensing agreement with Swiss pharma giant Roche’s (ROG: SIX) subsidiary Genentech, for the development,…...

3+ week, 5+ day ago   (243+ words) The Pharma Letter - Kynexis raises 97 million euros to advance med for cognitive disorders Dutch clinical-stage biotech Kynexis today announced the closing of a 40 million euros ($46.3 million) Series A extension bringing total Series A financing to 97 million euros ($110 million). The financing…...

4+ week, 1+ day ago   (314+ words) Deal-making news last week including Spanish dermatology specialist Almirall entering into a research collaboration with China’s CrystalO Biopharma. Sentynl entered a deal to license lung disease candidate alvelestat from Mereo BioPharma, which could earn the latter nearly half a billion…...